These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181 [TBL] [Abstract][Full Text] [Related]
6. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896 [TBL] [Abstract][Full Text] [Related]
7. A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques. Su JT; Simpson SM; Sung S; Tfaily EB; Veazey R; Marzinke M; Qiu J; Watrous D; Widanapathirana L; Pearson E; Peet MM; Karunakaran D; Grasperge B; Dobek G; Cain CM; Hope T; Kiser PF Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871073 [TBL] [Abstract][Full Text] [Related]
8. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746 [TBL] [Abstract][Full Text] [Related]
10. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis. Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467 [TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men. Han K; Wannamaker P; Lu H; Zhu B; Wang M; Paff M; Spreen WR; Ford SL Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205721. PubMed ID: 35129374 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459 [TBL] [Abstract][Full Text] [Related]
13. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR; Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299 [TBL] [Abstract][Full Text] [Related]
14. Formulation and pharmacology of long-acting cabotegravir. Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948 [TBL] [Abstract][Full Text] [Related]
15. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783 [TBL] [Abstract][Full Text] [Related]
16. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. Prather C; Jeon C Am J Health Syst Pharm; 2022 Oct; 79(21):1898-1905. PubMed ID: 35894204 [TBL] [Abstract][Full Text] [Related]
17. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor. Kovač L; Časar Z Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142 [No Abstract] [Full Text] [Related]